Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies
SGLT2i treatment was demonstrated to be cost-effective in both the T2DM population and the non-DM CKD population, suggesting the potential of SGLT2i to offer significant clinical and economic benefits in the comprehensive management of CRM diseases.
Authors
- Hiroki Akiyama (ORCID: https://orcid.org/0000-0003-2627-1055)
- Shun Kohsaka (ORCID: https://orcid.org/0000-0003-3779-2972)
- Naohiko Imai (ORCID: https://orcid.org/0000-0001-9984-2889)
- Keiko Maruyama‐Sakurai (ORCID: https://orcid.org/0000-0001-6100-2227)
- Ataru Igarashi (ORCID: https://orcid.org/0000-0001-6307-6916)
- Hisateru Tachimori (ORCID: https://orcid.org/0000-0001-6401-2885)
- Hiroyuki Takagi
- Hiroaki Miyata (ORCID: https://orcid.org/0000-0001-8800-6201)
- Yasumasa Segawa
Institutions
- Keio University (JP)
- Yokohama City Seibu Hospital (JP)
- AstraZeneca (Japan) (JP)
- Department of Health (IE)
- The University of Tokyo (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1007/s12325-025-03157-z
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- AstraZeneca
- University of Tokyo
- Program on Open Innovation Platform with Enterprises, Research Institute and Academia